3 studies from 2024 that show the power of using Datavant's technology to link de-deidentified datasets, offering the opportunity to use existing datasets to improve patient health outcomes.
🔎The Burden of Attention-Deficit/Hyperactivity Disorder in Adults: A Real-World Linked Data Study
🔗Linked data: 75,000+ National Health and Wellness Survey respondents ➕ 65B+ clinical, pharmacy, and laboratory encounters for 320M+ patients in the US from Komodo Health
➡️Conclusions: Patients with ADHD treated with longer DoE formulations had substantially better economic outcomes versus shorter DoE formulation or unmedicated groups, offering potential cost savings to the health care system and the patient. Furthermore, it is important to consider the effect of mental health comorbidities in the overall management of ADHD.
🔎Development of a Longitudinal Prostate Cancer Transcriptomic and Real-World Clinical Data Linkage
🔗Linked data: 95,578 patients with Decipher Prostate Genomic Classifier from Veracyte, Inc. ➕ 300M+ patients from Clarivate = 37+ M EHR records, 100M+ claims for 92,976 patients
➡️Conclusions: We established the first national-scale linkage of transcriptomic and longitudinal clinical data yielding high accuracy for identifying key clinical junctures including diagnosis, treatment, and early cancer outcome. This resource can be leveraged to enhance understandings of disease biology, patterns of care and treatment effectiveness.
🔎Racial and Socioeconomic Disparities Among Patients with Chronic Lymphocytic Leukemia (CLL) Treated in the US Community Oncology Setting
🔗Linked data: 12,000+ patients sourced from EHR iKnowMed ➕ Mortality and social determinants of health data (level of education, total household income) from Datavant.
➡️Conclusion: This study identifies racial disparities in this modern era of CLL therapy using real-world data from a large community setting in the US. Black race and low income are prognostic of less favorable OS in CLL. Further research is needed to determine whether racial and income disparities in CLL are due to differences in access to therapy, quality of care, disease biology, comorbidities or other factors. This research may contribute to developing interventions to ensure that progress in CLL therapy benefits all patients.
Datavant technology enabled a wide range of health research in 2023.
What questions do you want to answer in 2024?
https://hubs.ly/Q02fg7900
#healthcareinnovation #realworlddata #datalogistics #sdoh